skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

In-depth pharmaceutical market coverage

Datamonitor Healthcare | Pharma Intelligence

Discover unmet pharmaceutical needs. Effectively prioritize market opportunities. Deliver optimal returns. Datamonitor Healthcare’s in-depth expert data analysis and robust interactive data tools meet your needs and address your challenges in an ever-changing market.

How it helps

The breadth of coverage ensures you can assess revenue potential and identify competitive threats, market catalysts, and untapped new product development opportunities more holistically than ever before.

How it works

Content created by a global team of award-winning specialist analysts, and an easy-to-use interface that streamlines information gathering make Datamonitor Healthcare the go-to solution for the pharmaceutical and biotechnology industries.  

It offers:

  • Forecasts, built by our analysts, including patient-based, epidemiology, and sales forecasts
  • A myriad of interactive data tools, including treatment, standards of care by country, and patient-based disease forecasts, supported by large-scale primary research with physicians, payers, and key opinion leaders
  • Expert coverage and in-depth analysis of key diseases, companies, drugs and market trends

What's included

Pharma Intelligence: latest

  • Datamonitor Healthcare

    Neuropathic Pain Market and Forecast Analysis to 2026

    By Nicola Sawalhi-Leckenby 07 Sep 2018

    Big changes are coming to the neuropathic pain market – are you prepared? Take a look at the projected neuropathic pain drug sales for the US, Japan, and five EU nations with the latest infographic from Datamonitor Healthcare. This snapshot view of the future of the neuropathic pain market is packed with data from the full Datamonitor Healthcare Neuropathic Pain Disease Coverage report.

  • Datamonitor Healthcare

    Meningococcal Vaccines Forecast Infographic

    By Karolina Kujawa 28 Aug 2018

    Over 1.2 million cases of bacterial meningitis are estimated to occur worldwide each year. If not treated promptly, up to half of those cases will be fatal. This infographic from Datamonitor Healthcare provides a snapshot of the meningococcal vaccines market in the US and five major EU markets. What does the meningococcal vaccines market have in store and how will it affect your business? Download now.

    Topic Vaccines

  • Datamonitor Healthcare

    Epidiolex and Epilepsy - big changes for medical marijuana

    By Stephanie Yip 28 Aug 2018

    With the FDA’s landmark approval of Epidiolex, a cannabidiol used to treat rare, severe pediatric epilepsies, the only obstacle to the legal sale of the drug is DEA reclassification of cannabidiol (CBD). With reclassification likely in the next 90 days, what does it mean for the epilepsy market, as well as the wider market for CBD?

    Topic Drug approval

  • Datamonitor Healthcare

    Japan Pharma Outlook 2027 Report Extract

    27 Aug 2018

    Download your complimentary Japan Pharma Outlook 2027 report extract. The 16-page excerpt includes highlights from the full report, which is available to subscribers of Datamonitor Healthcare, and available to purchase on our Report Store. Discover now the complex challenges and opportunities facing Japan Pharma.

  • Datamonitor Healthcare

    Trends in Gene Therapy Seminar

    By Patricia Reilly 22 Aug 2018

    The promises of gene therapy are taking a long time to be fulfilled, in part due to challenges in developing gene vectors capable of safe and efficient delivery of therapeutic genes (transgenes) into patients’ cells. Nonetheless, these challenges are being addressed in innovative ways. A variety of first-generation vectors, both viral and non-viral, have been employed in clinical trials with varying degrees of success, and the experience gained is guiding the design of next-generation vectors.

  • Datamonitor Healthcare

    Podcast - Analyst Opinion on Approval of AndexXa for reversal of Eliquis and Xarelto

    By Zachary McLellan 22 Aug 2018

    Zach McLellan, Jack Allen, and guest analyst Cameron Findlater discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including the approval of AndexXa for reversal of Eliquis and Xarelto & Eli Lilly's acquisition of ARMO Biosciences.

  • Datamonitor Healthcare

    Japan Pharma Outlook Webinar Recording

    By Ian Haydock 22 Aug 2018

    Listen to this insightful presentation of the unique challenges and opportunities faced by Japan Pharma, hosted by the expert analysts from Pharma Intelligence.

    Topic Drug development landscape

  • Datamonitor Healthcare

    Datamonitor Healthcare Analyst Podcast: Post-ASCO Podcast 2

    By Jack Allen 22 Aug 2018

    Zach McLellan and Jack Allen are joined by guest analyst Maria Berezina. The group discusses key recent events that occurred at the American Society of Clinical Oncology 2018 Annual Meeting.

    Topic Cancer

  • Datamonitor Healthcare

    Datamonitor Healthcare Analyst Podcast: Post-ASCO Podcast 1

    By Jack Allen 22 Aug 2018

    Zach McLellan and Jack Allen are joined by guest analysts Dominique Fontanilla and Hardik Patel. The group discusses key recent events that occurred at the American Society of Clinical Oncology 2018 Annual Meeting.

    Topic Cancer

  • Datamonitor Healthcare

    Business Development and Licensing Video

    01 Jul 2018

    If you’re a senior business development and licensing professional in pharma or biotech, it’s your job to ensure that your company’s revenue pipeline is full of viable opportunities and accelerate growth for your organisation. Watch this short video  and discover how Informa’s Pharma Intelligence provides the rock-solid intelligence you need to accelerate growth and drive business forward.

    Topic Business strategies

  • Datamonitor Healthcare

    Acute Myeloid Leukemia Market Outlook Seminar

    By Dominique Fontanilla 27 Jun 2018

    There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.

    Topic Cancer

  • Datamonitor Healthcare

    Approval of Sun Pharmas Yonsa in Prostate Cancer Podcast

    By Zachary McLellan 29 May 2018

    Zach McLellan and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including the approval of Sun Pharma's Yonsa in prostate cancer, and broad market commentary on Tesaro, Gilead, Clovis, Portola, BMS and Celgene

    Topic Company analysis

  • Citeline, Scrip, Biomedtracker, Datamonitor Healthcare

    ASCO Essentials Webinar 2018 Recording

    By Mary Jo Laffler 29 May 2018

    Just in time for your 2018 ASCO Annual Meeting planning, join analysts from Datamonitor Healthcare, Biomedtracker, Citeline, Scrip, and Pink Sheet for their expert opinions on what you need to know to get the most from the meeting. Let our experts present their top picks from the thousands of abstracts being presented at ASCO.

    Topic Clinical trials

  • Datamonitor Healthcare

    Profitability Assessment of Branded Generic Inhalers

    By Ljlal Syed, Mark Lansdell and David Abramson 17 May 2018

    This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic

    Topic Deal trends

  • Datamonitor Healthcare

    Gene therapy

    15 May 2018

    Topic Cell and gene therapy

Meet the team

Analyst

Rachel Meighan-Mantha

Analyst, Principal Analyst
Rachel Meighan-Mantha

Rachel specializes in

  • Oncology
  • Clinical Trials

+22 year(s) experience

Analyst

Amanda Micklus

Analyst, Principal Analyst

Connecticut

Amanda Micklus

Amanda specializes in

  • Oncology
  • Business Development & Licensing
  • Commercial Strategy

+18 year(s) experience

Management

Michael Hay

Management, Head of Intelligence Products
Michael Hay

Michael specializes in

  • Business Development & Licensing
  • Commercial Strategy

+18 year(s) experience

Keep up to date

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: